To Be Discontinued Injection Oncology

Decitabine Injection · 203 days since initial FDA posting

Brand: DECITABINE

FDA lists Decitabine Injection as To Be Discontinued (Ingenus Pharmaceuticals LLC).

No availability text on this FDA row.

Decitabine Injection: To Be Discontinued

FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.

Shortage Details

Generic Name
Decitabine Injection
Manufacturer
Ingenus Pharmaceuticals LLC
Dosage Form
Injection
Presentation
Decitabine, Injection, 50 mg (NDC 68001-573-41)
Package NDC
68001-573-41

Status & Timeline

Status
To Be Discontinued
First Reported
Feb 20, 2026
Last Updated
Feb 20, 2026
Therapeutic Category
Oncology

Row fields from the FDA Drug Shortages database via openFDA.

Shortage Reason

Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug

Nearby, Other Decitabine Shortage Records

Decitabine Injection

Ingenus Pharmaceuticals LLC

Injection

To Be Discontinued

FDA reason on file: Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.

← All Drug Shortages